Norwegian version of this page

Translational and Computational Research on Solid and Hematological Cancer

Our aim is to identify biomarkers (genes, gene products and pathways) of diagnostic, prognostic and predictive relevance in serous effusions, uterine sarcomas, melanoma, lymphoma, leukemia, and pediatric tumors.

We aim to identify potential therapeutic targets and develop a screening platform facilitating clinical treatment decision. We do computational biology related research and also provide various research services for national and international clinical trials including molecular testing, flow cytometry and central pathology review.


  • Chemoresistance-related markers in ovarian carcinoma
  • Mutation profiles, NGS and tumor heterogeneity in ovarian carcinoma
  • Diagnostic and prognostic markers in uterine sarcoma
  • Optimizing an ex-vivo assay to evaluate clinical treatment response
  • Identification of mechanisms for treatment resistance in melanoma
  • Molecular characterization of cold agglutinin disease
  • Characterization of subtypes and new biological markers in peripheral T-cell lymphoma
  • NGS of relapsed/refractory diffuse large B-cell lymphoma and transformed follicular lymphoma
  • Molecular profiling, predictive/prognostic biomarkers and MRD detection in neuroblastoma
  • Building next generation predictive models in computational cancer biology


Published May 3, 2017 8:30 AM - Last modified Aug. 10, 2020 1:32 PM


Group leader


Detailed list of participants